Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
|
6 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | ||||
---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
Sep. 30, 2013
Segment
Vendor
|
Sep. 30, 2012
|
Aug. 31, 2012
Financing Agreement with Biopharma
|
Jun. 30, 2013
Specialty pharmacy
Customer
|
Sep. 30, 2013
Minimum
|
Sep. 30, 2013
Maximum
|
Aug. 31, 2012
Maximum
Financing Agreement with Biopharma
|
|
Accounting Policies [Line Items] | ||||||||
Additional cash and cash equivalents, description | We consider all highly liquid investments purchased with maturities of three months or less from the date of purchase to be cash equivalents. | |||||||
Percentage of sales to one specialty pharmacy customer | 97.00% | |||||||
Number of customer | 1 | |||||||
Number of manufacturer | 1 | |||||||
Property and equipment, estimated useful life | 3 years | 5 years | ||||||
Debt issuance date | Aug. 02, 2012 | |||||||
Proceeds from issuance of long-term obligation, net of cash paid for issuance costs | $ 29,860,000 | $ 30,000,000 | ||||||
Total amount to be paid related to debt | $ 45,000,000 | |||||||
Payment terms for discount on sales of Korlym sales | 30 days | |||||||
Product returns period prior to expiration date to provide credit | 6 months | |||||||
Product returns period after expiration date to provide credit | 12 months | |||||||
Number of operating segment | 1 | |||||||
Probability percentage for achieving performance-based vesting criteria for expense recognition | 70.00% |